- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Cognition Therapeutics, Inc.: Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results | 1 | GlobeNewswire (USA) | ||
| 17.03. | Cognition Therapeutics präsentiert positive Studiendaten zum Demenz-Wirkstoff Zervimesine | 1 | Investing.com Deutsch | ||
| 17.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 | 2 | GlobeNewswire (USA) | ||
| 02.03. | Cognition Therapeutics shifts focus to DLB psychosis treatment | 1 | Investing.com | ||
| 02.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis | 239 | GlobeNewswire (Europe) | PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders... ► Artikel lesen | |
| 02.03. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.02. | Cognition Therapeutics, Inc.: Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | 3 | GlobeNewswire (USA) | ||
| 27.01. | Cognition Therapeutics bespricht mit FDA nächste Studienphase für Demenz-Medikament | 1 | Investing.com Deutsch | ||
| 27.01. | Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug | 2 | Investing.com | ||
| 27.01. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 27.01. | Cognition Therapeutics, Inc.: Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies | 186 | GlobeNewswire (Europe) | PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders... ► Artikel lesen | |
| 06.01. | Cognition Therapeutics, Inc.: Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies | 4 | GlobeNewswire (USA) | ||
| 18.12.25 | COGNITION THERAPEUTICS INC - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | Cognition Therapeutics, Inc.: Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | 176 | GlobeNewswire (Europe) | PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative... ► Artikel lesen | |
| 01.12.25 | Cognition Therapeutics outlines Phase 3 plans for Alzheimer's drug | 4 | Investing.com | ||
| 13.11.25 | Cognition Therapeutics completes enrollment in Alzheimer's drug trial | 1 | Investing.com | ||
| 13.11.25 | Cognition Therapeutics, Inc.: Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease | 198 | GlobeNewswire (Europe) | PURCHASE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders... ► Artikel lesen | |
| 06.11.25 | Cognition Therapeutics GAAP EPS of -$0.06 | 2 | Seeking Alpha | ||
| 06.11.25 | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs | 231 | GlobeNewswire (Europe) | - $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for... ► Artikel lesen | |
| 06.11.25 | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | 1 | SEC Filings |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,05 | -1,36 % | Nach eigenem Bekunden konzentriert sich BioNTech bei der Suche nach einem neuen CEO vor allem auf die USA | Der kürzlich angekündigte Rücktritt der BioNTech Gründer Ugur Sahin und Özlem Türeci sorgte für einen Schock an der Börse und auch anderswo für Unsicherheit. Die Stadt Mainz scheint bereits darum zu... ► Artikel lesen | |
| AMGEN | 302,70 | +0,51 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| NOVAVAX | 8,296 | -0,73 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 158,45 | 0,00 % | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,000 | +0,09 % | Why Viking Therapeutics Stock Could Take Off Later This Year | ||
| MAINZ BIOMED | 0,473 | 0,00 % | Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors | BERKELEY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber (the "Company" or "Quantum Cyber"), today announced a strategic update in response... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,050 | -1,16 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 42,600 | +4,41 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 9,914 | +14,59 % | BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz | ||
| BIOMARIN PHARMACEUTICAL | 46,110 | -1,41 % | BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO | ||
| SAREPTA THERAPEUTICS | 15,005 | +3,66 % | Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies | ||
| EXELIXIS | 36,340 | +1,91 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,196 | +4,42 % | Canaccord reiterates Pacific Biosciences stock rating on new chemistry | ||
| CARDIOL THERAPEUTICS | 0,800 | -0,74 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| VAXART | 0,420 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
Das Unternehmen COGNITION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +6,64 % bei einem Aktienkurs von 1,125 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGNITION THERAPEUTICS INC finden Sie auf Wallstreet Online.